Search research articles
Contact Us
Filters
Showing results (51-60 of 97) with videos related to
Page
of 10
Sort By:
The Journal of Urology
|
October 1, 1991
Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate
A Dupont, L Cusan, J L Gomez, et al.
British Journal of Urology
|
November 1, 1993
Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma
A Dupont, L Cusan, J L Gomez, et al.
The Prostate
|
May 1, 1994
Metastatic prostate cancer pulmonary nodules: beneficial effects of combination therapy and subsequent withdrawal of flutamide
L Cusan, J L Gomez, A Dupont, et al.
Urology
|
February 1, 1996
Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen
F Labrie, B Candas, L Cusan, et al.
Endocrinology
|
May 1, 1979
Inhibitory effects of long term treatment with a luteinizing hormone-releasing hormone agonist on the pituitary-gonadal axis in male and female rats
L Cusan, C Auclair, A Belanger, et al.
Nature
|
August 11, 1977
Potent prolactin and growth hormone releasing activity of more analogues of Met-enkephalin
L Cusan, A Dupont, G S Kledzik, et al.
The Journal of Urology
|
March 1, 1992
Serum prostate specific antigen as pre-screening test for prostate cancer
F Labrie, A Dupont, R Suburu, et al.
The American Journal of Medicine
|
May 1, 1992
Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients
J L Gomez, A Dupont, L Cusan, et al.
The Journal of Clinical Endocrinology and Metabolism
|
October 1, 1994
Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men
A Bélanger, B Candas, A Dupont, et al.
Nature Medicine
|
February 1, 1995
The impact of family history on early detection of prostate cancer
S A Narod, A Dupont, L Cusan, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 97) with videos related to
Sort By:
Page
of 10
The Journal of Urology
|
October 1, 1991
Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate
A Dupont, L Cusan, J L Gomez, et al.
British Journal of Urology
|
November 1, 1993
Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma
A Dupont, L Cusan, J L Gomez, et al.
The Prostate
|
May 1, 1994
Metastatic prostate cancer pulmonary nodules: beneficial effects of combination therapy and subsequent withdrawal of flutamide
L Cusan, J L Gomez, A Dupont, et al.
Urology
|
February 1, 1996
Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen
F Labrie, B Candas, L Cusan, et al.
Endocrinology
|
May 1, 1979
Inhibitory effects of long term treatment with a luteinizing hormone-releasing hormone agonist on the pituitary-gonadal axis in male and female rats
L Cusan, C Auclair, A Belanger, et al.
Nature
|
August 11, 1977
Potent prolactin and growth hormone releasing activity of more analogues of Met-enkephalin
L Cusan, A Dupont, G S Kledzik, et al.
The Journal of Urology
|
March 1, 1992
Serum prostate specific antigen as pre-screening test for prostate cancer
F Labrie, A Dupont, R Suburu, et al.
The American Journal of Medicine
|
May 1, 1992
Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients
J L Gomez, A Dupont, L Cusan, et al.
The Journal of Clinical Endocrinology and Metabolism
|
October 1, 1994
Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men
A Bélanger, B Candas, A Dupont, et al.
Nature Medicine
|
February 1, 1995
The impact of family history on early detection of prostate cancer
S A Narod, A Dupont, L Cusan, et al.
Page
of 10